These results are consistent with publications showing that, although ILC tumors overall have low response rates to NAC, the subset of ILC with high-risk biology appears to garner similar benefit as triple-negative or HER2+ invasive ductal carcinoma.22,23 This represents an appropriate tailoring of therapy not only by histologic subtype, but by receptor subsets within ILC. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.